Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Kaletra

Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 25–26

HOS-108940 · Präparat HOS-093083

Methadone Methadone: ↓ Monitoring plasma concentrations of methadone is recommended. Oral contraceptives Ethinyl Oestradiol Ethinyl Oestradiol: ↓ In case of co-administration of Kaletra with contraceptives containing ethinyl oestradiol (whatever the contraceptive formulation e.g. oral or patch), additional methods of contraception must be used. Smoking cessation aids Bupropion Buproprion and its active If the co-administration of Kaletra metabolite, hydroxybupropion: with bupropion is judged AUC and Cmax ↓ ~50% unavoidable, this should be done under close clinical monitoring for This effect may be due to bupropion efficacy, without induction of bupropion exceeding the recommended metabolism. dosage, despite the observed induction. Thyroid hormone replacement therapy Levothyroxine Post-marketing cases have been Thyroid-stimulating hormone reported indicating a potential (TSH) should be monitored in interaction between ritonavir patients treated with levothyroxine containing products and at least the first month after levothyroxine. starting and/or ending lopinavir/ritonavir treatment. Vasodilating agents 25  Bosentan Lopinavir - ritonavir: Caution should be exercised in Lopinavir/ritonavir plasma administering Kaletra with concentrations may decrease due bosentan. to CYP3A4 induction by When Kaletra is administered bosentan. concomitantly with bosentan, the efficacy of the HIV therapy should Bosentan: be monitored and patients should AUC: ↑ 5-fold be closely observed for bosentan Cmax: ↑ 6-fold toxicity, especially during the first Initially, bosentan Cmin: ↑ by week of co-administration. approximately 48-fold. Due to CYP3A4 inhibition by lopinavir/ritonavir. Riociguat Serum concentrations may be The co-administration of riociguat increased due to CYP3A and with Kaletra is not recommended P-gp inhibition by (see section 4.4 and refer to lopinavir/ritonavir. riociguat SmPC). Other medicinal products Based on known metabolic profiles, clinically significant interactions are not expected between Kaletra and dapsone, trimethoprim/sulfamethoxazole, azithromycin or fluconazole.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) bupropion (HOS-086329) riociguat (HOS-086293) methadone (HOS-086198) trimethoprim (HOS-085184) azithromycin (HOS-088112) fluconazole (HOS-087945) bosentan (HOS-086291) dapsone (HOS-088141) levothyroxine (HOS-086339)